abstract |
The present application relates to 5-HT 6 New uses of receptor antagonists, specifically high doses of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline, and 5-HT 6 Receptor antagonists, in particular 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline, and acetylcholinesterase inhibitors for the treatment of neurodegenerative diseases. |